Bilirubin
Cytochrome C
Gastric Mucin
HCG
FSH
UTI
PMSG
Aprotinin
Asparaginase
Beta Glucanase
Bromelain
Chymotrypsin
Kallikrein
Lysozyme
Pancreatin
Papain
Pepsin
Streptokinase
Trypsin
Urokinase
Coenzyme A
Coenzyme A Trilithium
Coenzyme Q10
Beta Glucans
Chitosan
Chondroitin Sulfate
Dextran
Dextran Sulfate Sodium
Glucosamine HCl
Heparin Sodium
Heparinoid
Hyaluronic Acid
Rosemary Extract
Sodium Cholate
Bilirubin
Cytochrome C
Gastric Mucin
HCG
FSH
UTI
PMSG
Aprotinin
Asparaginase
Beta Glucanase
Bromelain
Chymotrypsin
Kallikrein
Lysozyme
Pancreatin
Papain
Pepsin
Streptokinase
Trypsin
Urokinase
Coenzyme A
Coenzyme A Trilithium
Coenzyme Q10
Beta Glucans
Chitosan
Chondroitin Sulfate
Dextran
Dextran Sulfate Sodium
Glucosamine HCl
Heparin Sodium
Heparinoid
Hyaluronic Acid
Rosemary Extract
Sodium Cholate
Jiagen Biotechnologies
Enzymes

Kallikrein

CAS No:9001-01-08
EINECS No:232-574-5
EC No:3.4.21.35
Synonyms:Bradykininogenase, callicrein, depot-padutin, glumorin, pancreatic kallikrein, kallikrein, kininogenin, kininogenase, kallidinogenase, porcine pancreatic kallikrein, kallikrein from porcine pancreas, kallikrein from hog pancreas, padreatin, padutin

Product Summary

Porcine pancreatic kallikrein is a serine protease purified from porcine pancreas, known for its ability to generate bradykinin from kininogen. The enzyme acts optimally near pH 8.0–8.7, hydrolyzing Arg-X peptide bonds such as BAEE. It serves as a model protease for enzyme kinetics, activation studies, MMP-9 zymogen activation, and cell-based assays - especially those involving neural progenitor proliferation. It has recently been adopted in immobilized-enzyme microfluidic / LC-MS platforms.

Function

Porcine pancreatic kallikrein functions by specifically cleaving low-molecular-weight or high-molecular-weight kininogen (LMWK or HMWK), which are circulating plasma precursors, to release bradykinin—a biologically active nonapeptide known for its potent vasoactive and pro-inflammatory properties. Once bradykinin is generated, it acts on bradykinin B2 receptors located on endothelial and smooth muscle cells, leading to a cascade of physiological effects, including vasodilation, blood pressure regulation, inflammation, and pain signaling.

Mechanism of Action

Porcine pancreatic kallikrein is a serine protease whose enzymatic activity centers on the selective cleavage of specific peptide bonds within kininogen, a glycoprotein precursor of bradykinin. The enzyme primarily hydrolyzes peptide bonds at the carboxyl side of arginine (Arg–X) residues, where "X" can be any amino acid, though certain neighboring residues influence substrate specificity.

  1. Catalytic process

    The catalytic mechanism of porcine pancreatic kallikrein involves a highly conserved catalytic triad—Histidine (His), Aspartate (Asp), and Serine (Ser)—which is characteristic of the trypsin-like subclass of serine proteases. These three amino acid residues work synergistically to cleave peptide bonds. His acts as a base to deprotonate the hydroxyl group of the serine residue. Ser, now nucleophilic, attacks the carbonyl carbon of the target peptide bond within kininogen. Asp stabilizes the positive charge developed on histidine during catalysis. This results in the formation of a tetrahedral intermediate, followed by bond cleavage and release of the bradykinin peptide, along with regeneration of the active site.

  2. Activation mechanism

    Kallikrein is synthesized as an inactive precursor (zymogen) called prokallikrein. It requires proteolytic activation to become enzymatically active:

    • Trypsin, a serine protease found in the pancreas, can cleave a specific activation peptide in prokallikrein to convert it into active kallikrein.
    • Alternatively, kallikrein may undergo autolytic cleavage, where an already active kallikrein molecule activates additional prokallikrein molecules—creating a positive feedback loop.

    This activation mechanism ensures that kallikrein remains dormant until needed, preventing unintended proteolytic activity in the pancreas or bloodstream.

  3. Substrate specificity and product formation

    Once activated, kallikrein targets low- and high-molecular-weight kininogens, cleaving specific Arg–Ser or Arg–Met bonds to release bradykinin (a 9-amino-acid peptide). This process is central to initiating the kinin cascade, leading to downstream effects such as increased vasodilation, stimulation of inflammatory pathways, activation of pain receptors, and facilitation of immune cell migration.

Applications in Scientific Research

  1. Physiological studies

    Porcine pancreatic kallikrein is extensively used as a biological tool in studies of the kallikrein–kinin system, a critical hormonal cascade regulating numerous physiological processes. By catalyzing the release of bradykinin, it enables researchers to:

    • Investigate vasodilation and vascular permeability mechanisms, especially in relation to blood pressure regulation.
    • Explore its role in inflammation, pain perception, and smooth muscle contraction.
    • Model systemic responses such as hypotension, shock, and allergic reactions, providing insight into inflammatory diseases, cardiovascular dysfunction, and asthma.

    This has been essential in understanding how kallikrein modulates vascular tone and inflammatory signaling in both normal and pathological states.

  2. Enzyme activation and kinetics studies

    Due to its trypsin-like serine protease nature and clear activation mechanism, porcine kallikrein serves as a model enzyme for:

    • Studying zymogen activation, particularly prokallikrein-to-kallikrein conversion, revealing general principles of protease maturation.
    • Elucidating enzyme-substrate interaction dynamics and reaction kinetics of serine proteases, contributing to the understanding of proteolytic cascades.
    • Acting as an activator of matrix metalloproteinase-9 (MMP 9) zymogen, which is relevant in extracellular matrix degradation, wound healing, and cancer metastasis.
  3. Cell culture and neuroscience applications

    Recent research has demonstrated that porcine kallikrein influences neural cell behavior, especially in neuroscience and developmental biology:

    • In subventricular zone (SVZ) neural progenitor cells, kallikrein exposure can modulate cell proliferation and survival, possibly through its bradykinin-mediated signaling.
    • It has also been shown to affect the fate and growth of oligodendrocyte progenitor cells, which are vital for myelination in the central nervous system.

    These findings suggest its utility in neural regeneration, brain injury models, and developmental neurobiology.

  4. Structural and functional enzymology
    Porcine pancreatic kallikrein has served as a model for high-resolution structural studies aimed at understanding serine protease mechanisms:
    • X-ray crystallographic studies, including those at ~2.0 Å resolution, have resolved the 3D structure of kallikrein A, revealing:
      • The detailed architecture of the active site.
      • The domain organization responsible for substrate recognition.
      • The conformational changes associated with zymogen activation.
    • These insights have furthered our understanding of substrate specificity, enzyme stability, and allosteric regulation within the serine protease family.

Packaging & Storage

  • Available as white to almost white lyophilized powder
  • Store in an airtight tamper-proof container at 2-8 °C

References

  1. Fiedler F, Leysath G. 1979: Substrate specificity of porcine pancreatic kallikrein, Adv Exp Med Biol. 120A: 261-71.
  2. Hojima Y, et al. 1977: Isolation and some properties of dog and rat pancreatic kallikreins, J Biochem. 81: 599-610.
  3. Jaffa AA, et al. 1986: A comparative study of prokallikreins and kallikreins from rat pancreatic tissue and juice, Adv Exp Med Biol. 198 Pt A: 323-7.
  4. Kizuki K, et al. 1982: Porcine pancreatic prokallikrein. I. Its partial purification and effects of various proteases on its activation, Chem Pharm Bull (Tokyo). 30(7): 2561-9.
  5. Moreau ME, et al. 2005: The kallikrein-kinin system: current and future pharmacological targets, J Pharmacol Sci. 99(1): 6-38.
  6. Björkqvist J, et al. 2013: Plasma kallikrein: the bradykinin-producing enzyme, Thromb Haemost. 110(3): 399-407.
  7. Motta G, Tersariol ILS. 2017: Modulation of the Plasma Kallikrein-Kinin System Proteins Performed by Heparan Sulfate Proteoglycans, Front Physiol. 11(8): 481.
  8. Schmaier AH. 2018: Plasma prekallikrein: Its role in hereditary angioedema and health and disease, Front Med (Lausanne). 25(5): 3.
  9. Vonnahme KA, et al. 1999: Detection of kallikrein gene expression and enzymatic activity in porcine endometrium during the estrous cycle and early pregnancy, Biol Reprod. 61(5): 1235-41.
  10. Valdés G, et al. 2001: Tissue kallikrein and bradykinin B2 receptor in human uterus in luteal phase and in early and late gestation, Endocrine 16(3): 207-15.
  11. Clements J, et al. 1994: Glandular kallikrein gene expression in the human uterus, Braz J Med Biol Res. 27(8): 1855-63.
  12. Devetzi M, et al. 2018: Genetically-modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)-based targeted therapy (Review), Int J Mol Med. 41(3): 1177-86.
  13. Goettig P, et al. 2010: Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs), Biochimie 92(11): 1546-67.
  14. Stefanini AC, et al. 2015: Involvement of kallikrein-related peptidases in normal and pathologic processes, Dis Markers. 2015: 946572.
  15. Chao J. 2013: Chapter 607-Human kallikrein 1, tissue kallikrein, Handbook Proteolytic Enzymes 3: 2757-61.
  16. Schmaier AH. 2016: The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities, J Thromb Haemost. 14(1): 28-39.
  17. Nunes VA, et al. 2003: Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site, J Protein Chem. 22(6): 533-41.
  18. Hooley E, et al. 2007: Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation, J Thromb Haemost. 5(12): 2461-6.
  19. Uehara S, et al. 1989: Role of the kallikrein-kinin system in human pancreatitis, Adv Exp Med Biol. 247B: 643-8.
  20. Reddigari S, Kaplan AP. 1988: Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma, Blood. 71(5): 1334-40.
  21. Vonnahme KA, et al. 2004: Porcine endometrial expression of kininogen, factor XII, and plasma kallikrein in cyclic and pregnant gilts, Biol Reprod. 70(1): 132-8.
  22. Fernando SC, et al. 2006: Porcine endometrial and conceptus tissue kallikrein 1, 4, 11, and 14 gene expression, Reproduction 132(6): 939-47.
  23. Wei Z, et al. 2018: Therapeutic values of human urinary kallidinogenase on cerebrovascular diseases, Front Neurol. 5(9): 403.

Jiagen Biotechnologies supplies quality Kallikrein of various specifications.
Contact us at sales@jiagen.ca to place an order.

Order